logo-loader
viewImugene Ltd

Imugene granted HER-Vaxx immunotherapy patent in the US; shares rise 12%

The patent provides method of composition and method of use protection to 2036.

Imugene Ltd - Imugene granted HER-Vaxx immunotherapy patent in the US; shares rise 12%
Imugene shares are trading about 12% higher intra-day, at 3.8 cents

Imugene Limited (ASX:IMU) has received a Notice of Grant from the US Patent and Trademark Office for its patent application for the HER-Vaxx cancer immunotherapy, currently in Phase II development for HER-2+ gastric cancer.

The patent titled ‘A vaccine composition and uses thereof’ protects the method of composition and method of use of Imugene’s HER-Vaxx for the generation of a therapeutic antibody response against HER-2/neu.

HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US7 billion per annum drug Herceptin.

HER-Vaxx has successfully completed a Phase Ib study in gastric cancer and the current stage of development is a Phase II study in gastric cancer.

Imugene managing director and CEO Leslie Chong said: “Attaining the key US patent is an important milestone.

“This adds extra value to HER-Vaxx as this will protect it in the world’s largest pharmaceutical market until 2036.”

Quick facts: Imugene Ltd

Price: 0.054 AUD

ASX:IMU
Market: ASX
Market Cap: $235.43 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene gets green light to start phase-1 clinical trial of new cancer...

Imugene Ltd's (ASX:IMU) Leslie Chong speaks to Proactive's Andrew Scott following the news it's received a second Human Research Ethics Committee approval to begin a phase-I clinical trial of its cancer checkpoint immunotherapy candidate, PD1-Vaxx. Ethics approval is confirmation that Imugene...

3 weeks, 3 days ago

2 min read